Bristol Myers Squibb-Pfizer Alliance Partners with Cost Plus Drugs for Eliquis Access
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Expanded Access Channels: The Bristol Myers Squibb-Pfizer Alliance has partnered with Cost Plus Drugs to offer Eliquis on CostPlusDrugs.com starting April 27, 2026, allowing cash-paying patients to purchase the medication for $345, significantly lowering access costs and enhancing patient availability.
- Market Demand Response: This collaboration addresses the strong market demand for Eliquis, with Cost Plus Drugs co-founder Mark Cuban emphasizing that patients should not have to guess medication prices, thereby providing a clearer and more direct access route that empowers patients.
- Healthcare Cost Savings: Eliquis is projected to save an estimated $3 billion in healthcare costs for every 100,000 patients treated, reducing hospitalization and rehabilitation needs, highlighting the drug's strategic importance in improving patient health and lowering overall healthcare expenditures.
- Continuation of Patient Support Programs: This partnership follows the 2025 launch of the Eliquis 360 Support program, further solidifying the BMS-Pfizer Alliance's commitment to patient resource support and aiming to enhance patient medication experiences through diversified access channels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.710
Low
37.00
Averages
55.86
High
68.00
Current: 58.710
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Stock Rises Over 20%
- Sales Outlook Decline: Bristol Myers Squibb anticipates total revenue to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, indicating vulnerability in the face of market challenges that may impact investor confidence.
- Strong Growth Segment Performance: Despite declining sales from its legacy portfolio, Bristol's growth segment achieved sales of $26.4 billion in 2025, up from $22.6 billion in 2024, demonstrating positive progress in new product development and offsetting legacy revenue declines.
- Dividend Appeal: The company currently offers a dividend yield of 4.26% and has increased its dividend for 17 consecutive years, making it attractive to investors seeking low-volatility investments and enhancing its appeal in uncertain markets.
- Low Volatility Advantage: With a beta of only 0.2, Bristol Myers Squibb exhibits significant price stability relative to market fluctuations, making its stock an ideal choice for long-term investment despite potential market volatility.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
Trump's White House Dinner Chaos Incident
- White House Dinner Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting the evacuation of Trump and other officials; Trump reported that one officer was shot but saved, highlighting the increasing political violence in the U.S.
- Iran Negotiation Cancellation: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks with Iran, stating that Iran could initiate dialogue by calling, which led Brent crude prices to surpass $106 per barrel, exerting downward pressure on stock futures.
- Fed Investigation Closure: The Justice Department ended its criminal investigation into Fed Chair Powell, clearing the way for Trump's nominee Warsh to gain support for confirmation, while Powell now faces a decision on whether to remain as a Fed governor after his term ends.
- Musk vs. Altman Trial: The trial between Musk and OpenAI CEO Altman begins today in Oakland, California, with Musk alleging in a $134 billion lawsuit that OpenAI failed to uphold its promise, which could significantly impact the future business trajectories of both tech leaders.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
Valuation Analysis of Bristol Myers Squibb Stock
- Valuation Appeal: Bristol Myers Squibb (BMS) has a forward P/E ratio of 9.4, significantly lower than the healthcare sector average of 17.3, indicating its stock may attract value investors, especially with a market cap of around $120 billion.
- Growth Prospects Challenges: Despite BMS's appealing growth potential, the looming patent cliff poses a significant risk for revenue decline in the coming years, particularly as its top drugs, Eliquis and Opdivo, face patent expiration in 2028, which could severely impact total revenue.
- Dividend Attraction: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors, who may prioritize steady cash flow over growth concerns.
- Competitor Comparison: Compared to competitors like Pfizer (PFE) and AbbVie, BMS's lower valuation may not be enough to offset the competitive pressure, as AbbVie appears more attractively valued when considering growth projections over the next five years.
See More
AstraZeneca's Saphnelo Approved for Self-Administration in the US
- Self-Administration Approval: AstraZeneca's Saphnelo has been approved in the US for self-administration as a once-weekly autoinjector, significantly enhancing patient convenience and expected to drive market demand.
- Clinical Trial Support: The approval is based on results from the Phase III TULIP-SC trial, demonstrating the efficacy of subcutaneous administration, further solidifying its position in systemic lupus erythematosus treatment.
- Global Market Expansion: Saphnelo is already approved for subcutaneous use in the EU and Japan, with regulatory reviews ongoing in several other countries, indicating AstraZeneca's potential for global market expansion.
- Licensing and Collaboration: AstraZeneca acquired global rights to Saphnelo through an exclusive license agreement with Medarex, and will pay Bristol-Myers Squibb a mid-teens royalty on US sales under an updated agreement in 2025, ensuring a continuous revenue stream.
See More
Bristol Myers Squibb Stock Rises Over 20%
- Sales Outlook Decline: Bristol Myers Squibb anticipates total revenue to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, indicating vulnerability in the face of market challenges that may impact investor confidence.
- Strong Growth Segment Performance: Despite declining sales from its legacy portfolio, Bristol's growth segment achieved sales of $26.4 billion in 2025, up from $22.6 billion in 2024, demonstrating positive progress in new product development and offsetting legacy revenue declines.
- Dividend Appeal: The company currently offers a dividend yield of 4.26% and has increased its dividend for 17 consecutive years, making it attractive to investors seeking low-volatility investments and enhancing its appeal in uncertain markets.
- Low Volatility Advantage: With a beta of only 0.2, Bristol Myers Squibb exhibits significant price stability relative to market fluctuations, making its stock an ideal choice for long-term investment despite potential market volatility.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
Trump's White House Dinner Chaos Incident
- White House Dinner Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting the evacuation of Trump and other officials; Trump reported that one officer was shot but saved, highlighting the increasing political violence in the U.S.
- Iran Negotiation Cancellation: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks with Iran, stating that Iran could initiate dialogue by calling, which led Brent crude prices to surpass $106 per barrel, exerting downward pressure on stock futures.
- Fed Investigation Closure: The Justice Department ended its criminal investigation into Fed Chair Powell, clearing the way for Trump's nominee Warsh to gain support for confirmation, while Powell now faces a decision on whether to remain as a Fed governor after his term ends.
- Musk vs. Altman Trial: The trial between Musk and OpenAI CEO Altman begins today in Oakland, California, with Musk alleging in a $134 billion lawsuit that OpenAI failed to uphold its promise, which could significantly impact the future business trajectories of both tech leaders.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
Valuation Analysis of Bristol Myers Squibb Stock
- Valuation Appeal: Bristol Myers Squibb (BMS) has a forward P/E ratio of 9.4, significantly lower than the healthcare sector average of 17.3, indicating its stock may attract value investors, especially with a market cap of around $120 billion.
- Growth Prospects Challenges: Despite BMS's appealing growth potential, the looming patent cliff poses a significant risk for revenue decline in the coming years, particularly as its top drugs, Eliquis and Opdivo, face patent expiration in 2028, which could severely impact total revenue.
- Dividend Attraction: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors, who may prioritize steady cash flow over growth concerns.
- Competitor Comparison: Compared to competitors like Pfizer (PFE) and AbbVie, BMS's lower valuation may not be enough to offset the competitive pressure, as AbbVie appears more attractively valued when considering growth projections over the next five years.
See More
AstraZeneca's Saphnelo Approved for Self-Administration in the US
- Self-Administration Approval: AstraZeneca's Saphnelo has been approved in the US for self-administration as a once-weekly autoinjector, significantly enhancing patient convenience and expected to drive market demand.
- Clinical Trial Support: The approval is based on results from the Phase III TULIP-SC trial, demonstrating the efficacy of subcutaneous administration, further solidifying its position in systemic lupus erythematosus treatment.
- Global Market Expansion: Saphnelo is already approved for subcutaneous use in the EU and Japan, with regulatory reviews ongoing in several other countries, indicating AstraZeneca's potential for global market expansion.
- Licensing and Collaboration: AstraZeneca acquired global rights to Saphnelo through an exclusive license agreement with Medarex, and will pay Bristol-Myers Squibb a mid-teens royalty on US sales under an updated agreement in 2025, ensuring a continuous revenue stream.
See More
